BiotechTubeBiotechTube
Home/Ovid Therapeutics/Thomas M. Perone
TM

Thomas M. Perone

Chief Business Officer and General Counsel

Ovid Therapeutics

Therapeutic Areas

Rare Neurological DiseasesEpilepsyNeurodevelopmental Disorders

Ovid Therapeutics Pipeline

DrugIndicationPhase
OV329 / TAK-935 (Soticlestat)Dravet Syndrome, Lennox-Gastaut SyndromePhase 3
OV350Angelman Syndrome (potential)Preclinical
OV882Angelman SyndromePreclinical
OV815Undisclosed rare neurological targetDiscovery

Leadership Team at Ovid Therapeutics

AR
Amit Rakhit
President, Chief Executive Officer, and Chairman of the Board
JL
Jennifer L. Bath
Senior Vice President, Head of Program and Alliance Management
MB
Matthew B. During
Founder and Director
JM
Jeremy M. Levin
Lead Independent Director
RP
Robert Poole
Chief Financial Officer (Interim)
RD
Randy D. Hice
Senior Vice President, CMC & Technical Operations
MS
Matthew S. Harlow
Chief Operating Officer
RZ
Ralph Z. Sorenson
Director
MA
Meg Alexander
Director
GC
G. Christian Andresen
Director
View full Ovid Therapeutics profile